Cite
HARVARD Citation
Yiming, R. et al. (2021). MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Cancer science. 112 (9), pp. 3810-3821. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Yiming, R. et al. (2021). MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Cancer science. 112 (9), pp. 3810-3821. [Online].